Praxis Precision (PRAX) Stock Skyrockets on Game-Changing Phase 3 Results – What Experts Say
Market Outlook With the stock now trading well above $150, investors are debating how much further PRAX could rise. If ulixacaltamide wins approval, analysts believe it could capture a sizable ET market.